ANDA 200875, held by Teva Parenteral. Levalbuterol Hydrochloride.
As of Nov 16, 2026, ANDA 200875 (Levalbuterol Hydrochloride), held by Teva Parenteral, was first approved by FDA on Sep 11, 2014, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 11, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Levalbuterol HydrochlorideEQ 0.25% BASE · solution;inhalation | Levalbuterol Hydrochloride | Rx |
| Feb 7, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 11, 2016 | Supplement 3Manufacturing | Approved | None posted |
| Nov 17, 2015 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 17, 2015 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 11, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters